Fertility Drugs Market Report 2025

This Fertility Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The fertility drugs market size has grown strongly in recent years. It will grow from $3.13 billion in 2024 to $3.36 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing infertility rates, advances in reproductive medicine, assisted reproductive technologies (ART), and delayed childbearing.

The fertility drugs market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.9% . The growth in the forecast period can be attributed to the aging population, lifestyle factors, assisted reproductive technologies (art), and personalized medicine. Major trends in the forecast period include advancements in assisted reproductive technologies (ART), ovulation-inducing medications, and hormone therapy.

The market for fertility drugs is experiencing growth due to the rising rates of infertility worldwide. Infertility is defined as the inability to conceive after 12 consecutive months of trying. Fertility drugs are commonly used to address infertility issues in both men and women. The increasing incidence of infertility can be attributed to physiological and hormonal issues, as well as lifestyle and environmental factors. In women, fertility drugs are often employed to regulate ovulation cycles, which directly impacts the sales of these medications. For example, a report from the Office for National Statistics in February 2024 indicated that the total fertility rate (TFR) in the UK fell to 1.49 children per woman in 2022, down from 1.55 in 2021. Consequently, the growing prevalence of infertility around the world is driving demand for fertility drugs, thereby contributing to the growth of the fertility drug market.

Anticipated growth in the fertility drugs market is further propelled by the mounting prevalence of obesity, a condition significantly associated with infertility in men and women. This trend stems from the imperative for specialized treatments, augmented awareness, supportive governmental policies, and ongoing research endeavors aimed at addressing fertility challenges linked to obesity. Data from the World Heart Federation in March 2023 reveals a staggering 2.3 billion individuals, both adults and children, affected by obesity or overweight conditions globally. Projections indicate an upward trend, with estimates foreseeing a rise to 2.7 billion by 2025. Thus, the burgeoning prevalence of obesity serves as a driving force propelling growth within the fertility drugs market.

Leading companies in the fertility drugs market are concentrating on creating innovative solutions, such as peptide-based injectable treatments, to improve reproductive health outcomes. Peptide-based injectable treatments involve medications that use synthetic or naturally occurring peptides to stimulate or regulate hormonal activity, particularly concerning fertility and reproductive health. For example, in February 2024, Lupin Limited, a pharmaceutical company based in India, introduced a ganirelix acetate injection in the United States. This medication is frequently used in assisted reproductive technology (ART) protocols to prevent premature ovulation during controlled ovarian stimulation for women undergoing in vitro fertilization (IVF). As a GnRH antagonist, ganirelix acetate helps regulate hormone levels, allowing for better management of the ovarian stimulation process. The launch in the U.S. underscores Lupin's commitment to expanding its product range in the reproductive health sector and addressing the needs of patients undergoing fertility treatments.

Major players in the fertility drugs market are launching comprehensive campaigns centered around fertility care, aiming to secure competitive advantages. These campaigns, designed to raise awareness and educate the public on fertility-related issues, treatments, and reproductive health, play a crucial role in safeguarding access to fertility care. Pinnacle Fertility's August 2022 initiative, the Save IVF campaign in the US, is a prime example. Focused on potential legislation affecting family-building treatments like IVF in the absence of federal protection, this campaign advocates for preserving fertility care access. By mobilizing communities and encouraging individuals to support the cause through the #SaveIVF Pledge, Pinnacle Fertility seeks to protect fertility treatments' accessibility and combat legislative threats.

In March 2023, Sumitovant Biopharma Ltd., a US-based biopharmaceutical company, finalized the acquisition of Myovant Sciences Ltd. for an undisclosed sum. This strategic acquisition amplifies Sumitovant's collaborative capabilities, resources, and expertise, enabling them to effectively tackle unmet needs in women's health and prostate cancer. The combined entity aims to advance their joint pipeline's development, extending the reach of their distinct therapies to benefit diverse patient communities. Myovant Sciences Ltd., a US-based biotechnology firm, specializes in developing and commercializing novel treatments for women's diseases and endocrine disorders. Their focus areas include addressing conditions like heavy menstrual bleeding associated with uterine fibroids and female infertility. This acquisition marks a pivotal step for both companies in bolstering their offerings and impact within these critical medical domains.

Fertility drugs encompass medications designed to stimulate the body's hormone release, regulating and prompting ovulation - the release of eggs from the ovaries.

These drugs fall into two main categories include prescription fertility drugs and over-the-counter variants. They are administered through various methods including oral ingestion, intravenous injection, subcutaneous injection (into the fatty tissue just below the skin), and intramuscular injection, catering to both male and female patients. Distribution channels for these drugs span hospital pharmacies, retail outlets, and online pharmacies, ensuring accessibility across different avenues for patients seeking fertility treatment.

The fertility drugs market research report is one of a series of new reports that provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the fertility drugs market include Merck & Co., Ferring Pharmaceuticals Inc., Bayer AG, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer Inc., Novartis AG, Procter & Gamble Health Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Abbott Laboratories, Sanofi S.A., Eli Lilly and Company, Serono Inc., Novagen Healthcare Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Schering-Plough Corporation, Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Vitrolife, Cook Medical, Organon Group, The Cooper Companies Inc., Irvine Scientific, Genea Biomedx, Mankind Pharma.

North America was the largest region in the fertility drugs market in 2024. The Middle East is expected to be the fastest-growing region in the drugs for infertility market during the forecast period. The regions covered in the fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.